Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill plus chemo takes on deadly pancreatic cancer in huge trial

NCT ID NCT07491445

Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 8 times

Summary

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assigned to one of three groups. The goal is to see if the new drug helps people live longer or keeps the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
daraxonrasib (a RAS inhibitor drug taken as pills), gemcitabine (chemo given by IV), nab-paclitaxel (chemo given by IV)
What this could lead to
If it works, this could offer a new first-line treatment option for people with metastatic pancreatic cancer, potentially extending life or slowing tumor growth.
What could go wrong
This is a large phase 3 trial, but the drug is still investigational. It may not improve outcomes over standard chemo, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent. * Documented RAS mutation status, either mutant or wild-type. * Measurable disease per RECIST v1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Able to take oral medications. Exclusion Criteria: * Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting. * Active or known history of untreated central nervous system metastatic disease. * Any conditions that may affect the ability to take or absorb study drug. * Major surgery within 28 days prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic adenosquamous carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma Pancreatic adenocarcinoma metastatic Pancreatic adenosquamous carcinoma Pancreatic cancer Pancreatic cancer metastatic Pancreatic ductal adenocarcinoma (PDAC) PDAC Pdac - pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    47 sites in 10 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Barts Hospital

    RECRUITING

    London, EC1A 7BE, United Kingdom

  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

    RECRUITING

    São Paulo, 09060-650, Brazil

  • CEPON - Centro de Pesquisa Oncologicas de Santa Catarina

    RECRUITING

    Florianópolis, Santa Catarina, 88034-000, Brazil

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Cancer Institute Hospital - Japan Foundation for Cancer Research

    RECRUITING

    Koto-Ku, Tokyo, 135-8550, Japan

  • Chiba Cancer Center

    RECRUITING

    Chiba, 260-8717, Japan

  • China Medical University Hospital

    RECRUITING

    Taichung, 40447, Taiwan

  • Comprehensive Cancer Centers of Nevada

    ACTIVE_NOT_RECRUITING

    Henderson, Nevada, 89052, United States

  • Curie Oncology Pte Ltd

    RECRUITING

    Singapore, 217562, Singapore

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Epworth HealthCare

    RECRUITING

    East Melbourne, Victoria, 3002, Australia

  • H Lee Moffitt Cancer Center and Research Institute

    RECRUITING

    Tampa, Florida, 33612, United States

  • Honor Health Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Email: •••••@•••••

  • Kanagawa Cancer Canter

    RECRUITING

    Kanagawa, 241-0815, Japan

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    RECRUITING

    Kaohsiung City, 80756, Taiwan

  • Krankenhaus der Barmherzigen Brüder Wien-Klinisch wissenschaftliche Studien

    RECRUITING

    Vienna, 1020, Austria

  • Kyushu University Hospital

    RECRUITING

    Fukuoka, 812-8582, Japan

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Mayo Clinic - Scottsdale

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Cancer Center- Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Cancer Center- Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • McGill University - Dept. Oncology Clinical Research Program

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • NHO Kyushu Cancer Center

    RECRUITING

    Fukuoka, 811-1395, Japan

  • NHS Cambridge of Addenbrooke Hospital

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • National Cancer Center - East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • National Cancer Center - Tokyo

    RECRUITING

    Tokyo, 104-0045, Japan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 100225, R.O.C, Taiwan

  • Osaka International Cancer Institute

    RECRUITING

    Osaka, 541-8567, Japan

  • Prince of Wales Hospital

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

  • Queen Elizabeth Hospital - Birmingham

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Royal Marsden Hospital - London

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • SCRI - Texas Oncology Dallas

    RECRUITING

    Dallas, Texas, 95246, United States

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Taylor Cancer Research Center

    ACTIVE_NOT_RECRUITING

    Maumee, Ohio, 43537, United States

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • Torbay Hospital

    RECRUITING

    Torquay, Devon, TQ2 7AA, United Kingdom

  • University of California Los Angeles Health - Hematology/Oncology

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Cincinnati Cancer Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Virginia Mason Medical Center

    RECRUITING

    Seattle, Washington, 98101, United States

  • Wakayama Medical University Hospital

    RECRUITING

    Wakayama, 641-8510, Japan

  • Yamaguchi University Hospital

    RECRUITING

    Yamaguchi, 755-8505, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.